Introduction
The aim of preventing preterm birth is to improve the health of babies by prolonging pregnancy. Preterm birth (PTB), or delivery before 37 weeks gestation, affects 7.3 % of pregnancies in the UK 1 . Around 75% result from spontaneous preterm labour. The remaining 25% are induced for medical reasons are not considered further in this article.
Who is at risk?
Specific obstetric clinical risk factors and / or ultrasound scan findings associated with an increased risk of spontaneous PTB are listed in box 1. However these have poor predictive value. Women with multiple pregnancy are also at high risk of preterm birth, and their management is discussed in supplementary online material.
Box 1: Risk factors for PTB 4 5 Clinical History*:
• *History of mid-trimester loss
• *History of preterm prelabour rupture of membranes in a previous pregnancy
• *History of PTB in a previous pregnancy
• *History of cervical treatment for CIN
The presence of any of these clinical risk factors can be considered a trigger for cervical length screening by transvaginal ultrasound scan.
Imaging:
• Short cervix (less than 25mm) on transvaginal ultrasound examination (Table 1) . However, considerable uncertainty exists over the effectiveness of these interventions, in part because clinical trials are hard to perform. Large numbers of trial participants are needed because the majority of high-risk women will deliver at term, even without treatment. It is both difficult and expensive to include neonatal and childhood outcomes in trials, therefore trials mainly focus on rates of preterm birth, not longer-term health outcomes of babies. Furthermore, inconsistencies in definitions, inclusion criteria and outcomes in studies mean it is difficult to summarise trial data in meta-analyses, and difficult to interpret relevance of the findings to individual women in the clinic setting.
What is the evidence of uncertainty?
See Table 2 for summary of evidence.
Singleton Pregnancies
Cervical Cerclage
An individual patient data (IPD) meta-analysis (5 RCTs involving 504 women) and a systematic review (12 RCTs involving 3328 women) showed that cervical cerclage delayed the gestational age at delivery and reduces PTB in women at risk of early delivery 7 8 . There was no statistically significant difference in perinatal mortality with cerclage, 7 8 . The IPD meta-analysis, which only included women with a short cervix (25mm), showed a reduction in composite neonatal morbidity in the cerclage group 7 .
However, no reduction in morbidity was seen in the larger meta-analysis of summary and caesarean section were found in those who underwent cerclage 8 .
Vaginal Progesterone
An IPD meta-analysis (5 RCTs involving 775 women and 827 infants) and a systematic review (36 RCTs involving 8523 women and 12,515 infants) support vaginal progesterone use to reduce PTB in women with singleton pregnancies at risk of PTB 9 10 . The results of both systematic reviews are mainly driven by one RCT in which all pregnant women were screened for cervical length with transvaginal ultrasound and progesterone given if the cervix was 10-20mm 11 . It is difficult to interpret these data where universal screening of cervical length in pregnancy is lacking, such as in the UK 12 .
A large UK based RCT (OPPTIMUM) was published after these systematic reviews and the release of NICE guidelines 13 . OPPTIMUM is the largest RCT of vaginal progesterone and the only one powered to include a childhood primary outcome. It included women at risk of PTB (Box 1) and found that vaginal progesterone did not reduce any of the primary outcomes: PTB, neonatal death or severe morbidity, or the childhood neurodevelopment development (standardised cognitive score (Bayley-III)) at 2 years of age 13 . There were no harms associated with progesterone use 13 .
Cervical Pessary
Two randomised trials of several hundred women have evaluated the Arabin pessary with a short cervix on transvaginal ultrasound 14 15 . The smaller trial reported a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 benefit in using the pessary 14 , whilst the larger trial found no statistically significant difference in PTB rate between women randomised to cervical pessary and those randomized to expectant management 15 .
Comparison of treatments to prevent PTB
As yet there are no reported trials comparing the effectiveness of cervical cerclage, progesterone supplementation and cervical pessary against each other when used in isolation or in combined management strategies in women at risk of PTB.
Multiple Pregnancies
Overall there is less evidence regarding management in multiple pregnancies. See Table 3 (online) for summary of evidence.
Cervical cerclage
A systematic review found no evidence that cervical cerclage reduces PTB in women with multiple pregnancy 16 . However, only 128 women with multiple pregnancy were included, firm conclusions about benefits and harms cannot be made.
Vaginal progesterone
Evidence from an IPD meta-analysis of 1,7345 women with multiple pregnancies shows no benefit from vaginal progesterone in this group as a whole 17 . However, progesterone did reduce poor perinatal outcome in a small subgroup of 116 women who had both multiple pregnancy and a short cervix. Further evidence is required to confirm this observation 17 . for preterm birth and found there was no difference between cervical pessary compared to routine care 18 19 . A third randomised controlled trial, confined to women with multiple pregnancy and a short cervix has recently been published, and did show a reduction in PTB with a cervical pessary 20 .
Is ongoing research likely to provide relevant evidence?
Clinical It is essential that future studies use standard definitions, protocols and core outcomes so that data regarding important, but uncommon outcomes (like neonatal mortality)
can be readily synthesized and guide decision-making. 
What should we do in the light of the uncertainty?
Parents should be aware that a reduction in incidence of early delivery may not necessarily translate into improved health in children.
It is reasonable to follow NICE (UK) guidance on the prevention of preterm birth and offer cervical cerclage when there has been a previous PTB, midtrimester loss, preterm prelabour rupture of membranes or cervical treatment, and the cervix is short 6 . Alternatively, progesterone may be offered 6 , however, the OPPTIMUM trial, (published after the NICE guideline), showed no benefit of vaginal progesterone in this group 13 . We were unable to find any international guidance relating to prevention of preterm birth.
We believe that further evidence is needed before offering the cervical pessary out of a research setting 14 15 .
In our opinion women with multiple pregnancies should not be offered treatments to prevent PTB (except in the context of clinical trials) as no clear benefit has been We suggest that clinicians share the uncertainly about PTB and offer women the opportunity to participate in relevant clinical trials.
What you need to know
• The best intervention for prevention of spontaneous PTB in women with risk factors is still unclear In women with a singleton pregnancy risk of PTB and a short cervix the evidence for use of cervical cerclage is clearer than that for progesterone or cervical pessary.
• Discuss with parents that prevention of pre term delivery may not necessarily translate into improved health in children.
BOX 3 Recommendations for future research

Future research should:
• Use standard definitions, protocols and core outcomes so that data can be meta-analysed.
• Be adequately powered for important outcomes including neonatal morbidity and periatal mortality, rather than surrogate outcomes such as PTB.
• Include consent to allow follow-up studies so that long term outcomes can be determined.
• Data from trials should be made available for subsequent meta-analysis
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Tables Table 1   Treatment What is it? Usual Timing Evidence and Guidance for use Cervical Cerclage A purse string suture that strengthens and tightens the cervix. Usually inserted under regional (spinal) or general anaesthesia.
Inserted between 12 and 24 weeks gestation, and removed at 37 weeks gestation or if there are signs of labour before this.
Current NICE guideline recommends offering cerclage to women with a clinical risk factor (Box 1) and a short cervix on ultrasound (<25mm) but mainly low or moderate quality evidence.
Progesterone supplements
Intravaginal progesterone is the only formulation available in the UK. Usually prescribed as once daily pessaries.
Commenced between 16 and 22 weeks gestation, and continued to 34-36 weeks gestation.
Current NICE guideline recommends offering vaginal progesterone to women with a clinical risk factor (Box 1) and/or a short cervix on ultrasound (<25mm) but mainly low or moderate quality evidence.
Cervical Pessary (Arabin)
A silicon ring that sits over the cervix and works by supporting the cervix and tilting it posteriorly. No anaesthesia or analgesia is required for insertion. There is only one cervical pessary on the market -Arabin.
Inserted between 18 and 22 weeks gestation, and removed at 37 weeks gestation or if there are signs of labour before this.
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